TY - JOUR
T1 - NCCN Guidelines® Insights
T2 - Bladder Cancer, Version 3.2024
AU - Flaig, Thomas W.
AU - Spiess, Philippe E.
AU - Abern, Michael
AU - Agarwal, Neeraj
AU - Bangs, Rick
AU - Buyyounouski, Mark K.
AU - Chan, Kevin
AU - Chang, Sam S.
AU - Chang, Paul
AU - Friedlander, Terence
AU - Greenberg, Richard E.
AU - Guru, Khurshid A.
AU - Herr, Harry W.
AU - Hoffman-Censits, Jean
AU - Kaimakliotis, Hristos
AU - Kishan, Amar U.
AU - Kundu, Shilajit
AU - Lele, Subodh M.
AU - Mamtani, Ronac
AU - Mian, Omar Y.
AU - Michalski, Jeff
AU - Montgomery, Jeffrey S.
AU - Parikh, Mamta
AU - Patterson, Anthony
AU - Peyton, Charles
AU - Plimack, Elizabeth R.
AU - Preston, Mark A.
AU - Richards, Kyle
AU - Sexton, Wade J.
AU - Siefker-Radtke, Arlene O.
AU - Stewart, Tyler
AU - Sundi, Debasish
AU - Tollefson, Matthew
AU - Tward, Jonathan
AU - Wright, Jonathan L.
AU - Cassara, Carly J.
AU - Gurski, Lisa A.
N1 - Publisher Copyright:
© 2024 Harborside Press. All rights reserved.
PY - 2024/5
Y1 - 2024/5
N2 - Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non–muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guerin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.
AB - Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non–muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guerin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.
KW - BCG Vaccine/therapeutic use
KW - Humans
KW - Male
KW - Neoplasm Staging
KW - Urinary Bladder Neoplasms/therapy
UR - http://www.scopus.com/inward/record.url?scp=85193502036&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2024.0024
DO - 10.6004/jnccn.2024.0024
M3 - Article
C2 - 38754471
AN - SCOPUS:85193502036
SN - 1540-1405
VL - 22
SP - 216
EP - 225
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 4
ER -
